Designing concept maps for a precise and objective description of pharmaceutical innovations

Abstract

BackgroundWhen a new drug is launched onto the market, information about the new manufactured product is contained in its monograph and evaluation report published by national drug agencies. Health professionals need to be able to determine rapidly and easily whether the new manufactured product is potentially useful for their practice. There is therefore a need to identify the best way to group together and visualize the main items of information describing the nature and potential impact of the new drug. The objective of this study was to identify these items of information and to bring them together in a model that could serve as the standard for presenting the main features of new manufactured product.MethodsWe developed a preliminary conceptual model of pharmaceutical innovations, based on the knowledge of the authors. We then refined this model, using a random sample of 40 new manufactured drugs recently approved by the national drug regulatory authorities in France and covering a broad spectrum of innovations and therapeutic areas. Finally, we used another sample of 20 new manufactured drugs to determine whether the model was sufficiently comprehensive.ResultsThe results of our modeling led to three sub models described as conceptual maps representingi) the medical context for use of the new drug (indications, type of effect, therapeutical arsenal for the same indications), ii) the nature of the novelty of the new drug (new molecule, new mechanism of action, new combination, new dosage, etc.), and iii) the impact of the drug in terms of efficacy, safety and ease of use, compared with other drugs with the same indications.ConclusionsOur model can help to standardize information about new drugs released onto the market. It is potentially useful to the pharmaceutical industry, medical journals, editors of drug databases and medical software, and national or international drug regulation agencies, as a means of describing the main properties of new pharmaceutical products. It could also used as a guide for the writing of comprehensive and objective texts summarizing the nature and interest of new manufactured product.

Development of a UK Online 24-h Dietary Assessment Tool: myfood24

“…Whilst the existing British food composition tables contain ~3500 generic food items [ 17 ], the food database developed for myfood24 contains ~45,000 UK branded and generic foods with their associated pack and portion sizes. The median adult SUS score of the myfood24 live version at 80/100 is in the “good” range for websites and compares favorably with other behavior-assessment websites, such as a smoking cessation website rated at 67 [ 31 ] and a physical activity website rated at 73 [ 32 ].…”

How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001–2012

“…However, we recognise that the criteria are qualitative rather than quantitative, requiring some value judgement to implement, and that some benefits or harms may not be apparent early in a product lifecycle, both of which could lead to misclassification (or differences in classification depending on viewpoint) that vary with time. Other commentators have further developed ideas of what constitutes therapeutic advantage and innovation to propose three axes of pharmaceutical innovation 22 : context of use (including existing treatment options), product novelty (chemical, pharmacological and pharmaceutical) and impact (efficacy, safety and ease of use with respect to existing therapies). However, none of these criteria take direct account of the public health and health service impact of a new drug (disease severity, patient group size and likely uptake); drugs in the highly innovative group include those for rare metabolic disorders and last line therapies as well as for diabetes mellitus and common malignancies.…”

Assessing Definitions and Incentives Adopted for Innovation for Pharmaceutical Products in Five High-Income Countries: A Systematic Literature Review

“…Iordatii et al define innovation as a new therapeutic option to treat a health problem for which there may already be an existing therapeutic arsenal that is targeting a disease, a symptom, or a risk factor. Innovation may lead to treatments that are easier to monitor, or doses that are easier to adjust for physicians [ 48 ]. According to Gonçalves et al, new therapeutic molecules that have the potential to radically transform the management and course of cancer, a product that—through a radical change—brings something new and that has the potential to constitute treatment in a situation where it did not exist previously or to improve clinically, can be defined as innovative.…”